Genesis Biomed to invest an additional €500,000 in 2020 Blog Post

The Genesis Ventures fund, investment vehicle of several family offices managed by the consulting firm Genesis Biomed, based in the Barcelona Science Park, has announced that it will invest an additional €500,000 in the remainder of this year. The new investments will be made in several of the spin-offs of its portfolio of companies dedicated to biomedical research, in a moment of paralysis due to health and social crisis caused by the SARS-CoV-2 coronavirus.

 

EQA develops The Conformity Assessment of Good Practice for Risk Management of COVID-19 Blog Post

EQA, an assessment and certification leading company accredited by ENAC (the Spain national accreditation agency) has developed The Conformity Assessment of Good Practice for Risk Management of COVID-19, as a basis for the progressive return to normality, essential for social and economic recovery. This evaluation is available for all types of facilities and services, whether they continue with their activity or prepare to start it.

 

Researchers identify a molecular auto-control system to avoid an excessive brown adipose tissue activity Blog Post

A scientific team found, lead by Professor Francesc Villarroya, from the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB) present in PCB, found a new molecular auto-control system of lipidic metabolism, so far unknown, could help prevent the damaging effects derived from an excessive activation of the brown adipose tissue. The study is published in the journal Nature Communications.

 

The FDA licenses Chemotargets CLARITY platform Blog Post

Chemotargets –a global leader in the development of intelligence platforms and drug design prediction, headquartered in the Barcelona Science Park– has signed a license agreement for its CLARITY® platform with the Food and Drug Administration (FDA) to provide adverse event predictions and mechanistic investigation in public health risk assessments of new drug applications and existing marketed products.

 

Esteve adds its weight to the fight against the pandemic through donations and research collaborations Blog Post

Esteve is participating in 3 European projects aimed at identifying and/or repositioning drugs that are active against COVID-19; at detecting SARS-CoV-2 ; and at analyzing the involvement of the sigma-1 receptor in the viral infection cycle. Additionally, the pharmaceutical group –which has its Drug Discovery and Preclinical Development Center at the Barcelona Science Park– has made donations targeted at health professionals, patients and people on the frontline of the COVID-19 pandemic.

 

Avinent collaborates with Althaia and other institutions to produce PPE with 3D printing technology Blog Post

The company Avinent, present in the Barcelona Science Park, is doing a collaborative project with Althaia Foundation, Bages University Foundation (FUB-UManresa), Eurecat, the Universitat Politécnica de Cataluña (UPC) and Manresa City Council to produce Personal Protective Equipment (PPE) with 3D printing technology. This alliance is concreted with the fabrication of face protection screens and door handles to open with the forearm.

 

Chemotargets opens an investment round to enter a new phase of growth Blog Post

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to expand its activity in the drug discovery sector as a biotechnology company. The company, based in the Barcelona Science Park, is opening an investment round to undertake the transformation of its business model, with tadvice and support of GENESIS Biomed, also located in the Park, and CREA Inversión.